4//SEC Filing
Anderson Karen M. 4
Accession 0001847903-24-000046
CIK 0001847903other
Filed
Mar 25, 8:00 PM ET
Accepted
Mar 26, 4:16 PM ET
Size
15.0 KB
Accession
0001847903-24-000046
Insider Transaction Report
Form 4
Anderson Karen M.
Chief People Officer
Transactions
- Exercise/Conversion
Ordinary Shares
2024-03-25$4.01/sh+25,010$100,290→ 102,695 total - Sale
Ordinary Shares
2024-03-25$11.66/sh−29,995$349,625→ 92,690 total - Exercise/Conversion
Ordinary Shares
2024-03-25$3.85/sh+19,990$76,962→ 122,685 total - Sale
Ordinary Shares
2024-03-25$12.21/sh−21,165$258,336→ 71,525 total - Exercise/Conversion
Share Option (right to buy)
2024-03-25−25,010→ 274,990 totalExercise: $4.01Exp: 2032-12-01→ Ordinary Shares (25,010 underlying) - Exercise/Conversion
Share Option (right to buy)
2024-03-25−19,990→ 60,010 totalExercise: $3.85Exp: 2033-02-01→ Ordinary Shares (19,990 underlying)
Footnotes (6)
- [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 23, 2023.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.07 to $12.035, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.07 to $12.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F5]25% of the shares subject to such option shall vest and become exercisable on December 1, 2023 and the remaining 75% of the shares subject to such option shall vest and become exercisable in 36 monthly installments on the first day of each month thereafter.
- [F6]1/48th of the shares subject to such option shall vest and become exercisable in equal monthly installments with the first installment vesting on March 1, 2023.
Documents
Issuer
Centessa Pharmaceuticals plc
CIK 0001847903
Entity typeother
Related Parties
1- filerCIK 0001762176
Filing Metadata
- Form type
- 4
- Filed
- Mar 25, 8:00 PM ET
- Accepted
- Mar 26, 4:16 PM ET
- Size
- 15.0 KB